Interferon therapy and prevention of hepatocellular carcinoma in hepatitis C.

Suppr

超能文献

作者信息

Singal Amit G, Marrero Jorge A

出版信息

Dig Dis Sci. 2012 Apr;57(4):832-4. doi: 10.1007/s10620-012-2069-8. Epub 2012 Feb 22.

DOI:10.1007/s10620-012-2069-8

PMID:22354544

Abstract

摘要

相似文献

Interferon therapy and prevention of hepatocellular carcinoma in hepatitis C.

Dig Dis Sci. 2012 Apr;57(4):832-4. doi: 10.1007/s10620-012-2069-8. Epub 2012 Feb 22.

Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C?干扰素疗法能否预防慢性丙型肝炎患者发生肝细胞癌？

Gastroenterology. 1999 Sep;117(3):738-9. doi: 10.1016/s0016-5085(99)70471-3.

Incomplete response of interferon treatment has an important role for the prevention of hepatocellular carcinoma.干扰素治疗反应不完全在预防肝细胞癌方面具有重要作用。

J Gastroenterol. 1999 Oct;34(5):655-6. doi: 10.1007/s005350050392.

Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C: flaws in the cure, or a clue to the flaws?非肝硬化丙型肝炎患者对干扰素持续应答后发生肝细胞癌：是治愈存在缺陷，还是缺陷的线索？

J Gastroenterol Hepatol. 1999 Sep;14(9):833-7. doi: 10.1046/j.1440-1746.1999.01977.x.

'Yes, now you are free from chronic HCV infection, but . . .'.“是的，现在你摆脱了慢性丙型肝炎病毒感染，但是……”

J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):9-10. doi: 10.1111/j.1440-1746.2005.04207.x.

[Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma].[干扰素联合利巴韦林治疗与肝细胞癌的发生]

Orv Hetil. 2010 Jul 18;151(29):1177-81. doi: 10.1556/OH.2010.28925.

Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.干扰素治疗不能预防丙型肝炎病毒代偿性肝硬化患者发生肝细胞癌。

Hepatogastroenterology. 2002 Nov-Dec;49(48):1636-8.

Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.慢性丙型肝炎患者肝细胞癌消融治疗后采用干扰素治疗进行复发的二级预防。

World J Gastroenterol. 2008 Oct 28;14(40):6140-4. doi: 10.3748/wjg.14.6140.

Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.持续病毒学应答对 HCV 肝硬化患者肝细胞癌发生率的影响。

Braz J Infect Dis. 2010 Sep-Oct;14(5):457-61.

Interferon therapy reduces the risk for hepatocellular carcinoma.干扰素治疗可降低肝细胞癌的风险。

Gut. 2000 Nov;47(5):610-1. doi: 10.1136/gut.47.5.610.

引用本文的文献

Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.系统评价与荟萃分析：直接作用抗病毒治疗后肝细胞癌的复发。

Aliment Pharmacol Ther. 2018 Jul;48(2):127-137. doi: 10.1111/apt.14823. Epub 2018 May 30.

Exosomes as potent regulators of HCC malignancy and potential bio-tools in clinical application.外泌体作为肝癌恶性肿瘤的有效调节因子及临床应用中的潜在生物工具。

Int J Clin Exp Med. 2015 Oct 15;8(10):17088-95. eCollection 2015.

本文引用的文献

Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.既往干扰素治疗对丙型肝炎病毒相关肝细胞癌根治性治疗后结局的影响。

Dig Dis Sci. 2012 Apr;57(4):1092-101. doi: 10.1007/s10620-011-1934-1. Epub 2011 Oct 12.

Boceprevir for untreated chronic HCV genotype 1 infection.博赛泼维用于治疗未经治疗的慢性 HCV 基因 1 型感染。

N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.聚乙二醇干扰素 alfa-2b 维持治疗不能预防肝硬化慢性丙型肝炎患者的肝细胞癌。

Gastroenterology. 2011 Jun;140(7):1990-9. doi: 10.1053/j.gastro.2011.03.010. Epub 2011 Mar 17.

Management of hepatocellular carcinoma: an update.肝细胞癌的管理：最新进展

Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.

Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.维持性聚乙二醇干扰素治疗与晚期丙型肝炎患者肝细胞癌发生的其他相关因素。

Gastroenterology. 2011 Mar;140(3):840-9; quiz e12. doi: 10.1053/j.gastro.2010.11.050. Epub 2010 Dec 1.

Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma.荟萃分析：干扰素改善肝癌消融或切除术的疗效。

Aliment Pharmacol Ther. 2010 Oct;32(7):851-8. doi: 10.1111/j.1365-2036.2010.04414.x.

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.持续的病毒应答与丙型肝炎病毒患者的肝脏相关发病率和死亡率降低相关。

Clin Gastroenterol Hepatol. 2010 Mar;8(3):280-8, 288.e1. doi: 10.1016/j.cgh.2009.11.018. Epub 2009 Nov 27.

Public health impact of antiviral therapy for hepatitis C in the United States.美国丙型肝炎抗病毒治疗对公共卫生的影响。

Hepatology. 2009 Dec;50(6):1750-5. doi: 10.1002/hep.23220.

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.特拉匹韦联合聚乙二醇干扰素和利巴韦林用于慢性丙型肝炎1型感染

N Engl J Med. 2009 Apr 30;360(18):1827-38. doi: 10.1056/NEJMoa0806104.

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.肝细胞癌：流行病学与分子致癌机制

Gastroenterology. 2007 Jun;132(7):2557-76. doi: 10.1053/j.gastro.2007.04.061.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验